Oceania Healthcare Limited

NZSE:OCA Stock Report

Market Cap: NZ$586.6m

Oceania Healthcare Valuation

Is OCA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of OCA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: OCA (NZ$0.78) is trading above our estimate of fair value (NZ$0.32)

Significantly Below Fair Value: OCA is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for OCA?

Other financial metrics that can be useful for relative valuation.

OCA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.6x
Enterprise Value/EBITDA181.5x
PEG Ratio0.7x

Price to Earnings Ratio vs Peers

How does OCA's PE Ratio compare to its peers?

The above table shows the PE ratio for OCA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average12.8x
ARV Arvida Group
8.9xn/aNZ$1.2b
SUM Summerset Group Holdings
7.2x0.4%NZ$2.9b
PHL Promisia Healthcare
16.1xn/aNZ$26.3m
GMPC Gulf Medical Projects Company (PJSC)
18.9xn/aد.إ1.3b
OCA Oceania Healthcare
17.9x26.2%NZ$586.6m

Price-To-Earnings vs Peers: OCA is expensive based on its Price-To-Earnings Ratio (17.9x) compared to the peer average (12.8x).


Price to Earnings Ratio vs Industry

How does OCA's PE Ratio compare vs other companies in the Global Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a10.7%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a10.7%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: OCA is good value based on its Price-To-Earnings Ratio (17.9x) compared to the Global Healthcare industry average (21.8x).


Price to Earnings Ratio vs Fair Ratio

What is OCA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OCA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio17.9x
Fair PE Ratio18x

Price-To-Earnings vs Fair Ratio: OCA is good value based on its Price-To-Earnings Ratio (17.9x) compared to the estimated Fair Price-To-Earnings Ratio (18x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst OCA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentNZ$0.78
NZ$0.98
+25.3%
15.5%NZ$1.21NZ$0.80n/a4
Oct ’25NZ$0.75
NZ$0.98
+30.3%
15.5%NZ$1.21NZ$0.80n/a4
Sep ’25NZ$0.81
NZ$0.96
+19.1%
16.5%NZ$1.21NZ$0.80n/a4
Aug ’25NZ$0.79
NZ$0.96
+22.0%
16.7%NZ$1.21NZ$0.80n/a4
Jul ’25NZ$0.54
NZ$0.94
+73.6%
20.5%NZ$1.21NZ$0.69n/a4
Jun ’25NZ$0.55
NZ$0.95
+72.7%
19.7%NZ$1.21NZ$0.69n/a4
May ’25NZ$0.58
NZ$0.93
+60.8%
19.1%NZ$1.19NZ$0.69n/a4
Apr ’25NZ$0.63
NZ$0.99
+57.5%
22.2%NZ$1.31NZ$0.69n/a4
Mar ’25NZ$0.59
NZ$0.99
+68.2%
22.2%NZ$1.31NZ$0.69n/a4
Feb ’25NZ$0.70
NZ$0.99
+41.1%
22.3%NZ$1.31NZ$0.69n/a4
Jan ’25NZ$0.76
NZ$0.99
+29.9%
22.3%NZ$1.31NZ$0.69n/a4
Dec ’24NZ$0.72
NZ$0.99
+37.2%
22.3%NZ$1.31NZ$0.69n/a4
Nov ’24NZ$0.69
NZ$1.03
+48.6%
23.2%NZ$1.38NZ$0.72NZ$0.794
Oct ’24NZ$0.71
NZ$1.06
+49.6%
22.1%NZ$1.38NZ$0.72NZ$0.754
Sep ’24NZ$0.76
NZ$1.07
+40.1%
22.3%NZ$1.39NZ$0.72NZ$0.814
Aug ’24NZ$0.77
NZ$1.07
+38.3%
22.3%NZ$1.39NZ$0.72NZ$0.794
Jul ’24NZ$0.77
NZ$1.07
+38.3%
22.3%NZ$1.39NZ$0.72NZ$0.544
Jun ’24NZ$0.80
NZ$1.07
+33.1%
22.3%NZ$1.39NZ$0.72NZ$0.554
May ’24NZ$0.70
NZ$1.15
+63.9%
26.6%NZ$1.48NZ$0.66NZ$0.584
Apr ’24NZ$0.73
NZ$1.24
+69.2%
14.1%NZ$1.48NZ$1.01NZ$0.634
Mar ’24NZ$0.77
NZ$1.25
+62.3%
12.5%NZ$1.48NZ$1.07NZ$0.594
Feb ’24NZ$0.90
NZ$1.27
+41.1%
11.1%NZ$1.48NZ$1.10NZ$0.704
Jan ’24NZ$0.76
NZ$1.27
+67.1%
11.1%NZ$1.48NZ$1.10NZ$0.764
Dec ’23NZ$0.84
NZ$1.27
+51.2%
11.1%NZ$1.48NZ$1.10NZ$0.724
Nov ’23NZ$0.83
NZ$1.46
+75.3%
15.3%NZ$1.77NZ$1.20NZ$0.694

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies